Reference: G0800026 Abstract: n.a PROJECT DETAILS beginning: 2008. end: 2012. Country of research: United Kingdom Counry of funding source: United Kingdom Funding organization: Medical Research Council Financing: NATIONAL FUNDINGS – 954 998 € hyperlink
Reference: na Abstract: n.a PROJECT DETAILS beginning: 2012. end: 2014. Country of research: Italy Counry of funding source: Italy Funding organization: Ministry of Health Financing: NATIONAL FUNDINGS – 284 440 € hyperlink
Reference: 73430 Abstract: The study design is the natural extension of our previous research works that had already been supported (www.humangenom.hu, www.eurosca.org). It is clear nowadays, that the functions of the carnitine are not restricted to the role of the oxidation of the long-chain fatty acids. The main direction of the planned research is the … Read more
Reference: ANRn.a.8-MNPSn.a.007 Abstract: Psychotic disorders (schizophrenia, bipolar disorder, pervasive developmental disorders) are disabling disorders of variable clinical expression ?, ?d resulting interaction between genetic and environmental factors during critical periods of brain development. Some candidate genes have been identified . Among them, neuregulin, RGS4, DISC1, reelin, BDNF and glutamatergic receptors are involved in the formation … Read more
Reference: B03 – Subproject to SFB 992: Medical Epigenetics (MEDEP) From basic mechanisms to clinical applications Abstract: The methyl-CpG-binding protein 2 (MeCP2) detects symmetrically methylated cytosine-guanine sequences (CpG) in the genomic DNA and modulate gene expression by recruiting coactivator and corepressor-proteins.ﾠWe found that MeCP2 is significantly downregulated in hypertrophic and failing heart.ﾠThe functional significance of … Read more
By continuing to use the site, you agree to the use of cookies. more information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
